

## WELL FUNDED TO ADVANCE DEVELOPMENT AND COMMERCIAL ACTIVITIES

Lodging this quarterly update, Chairman David Williams said: “Our recent capital raise of \$9.4m plus attaching options is evidence of the value shareholders place on the prospects of our cancer diagnostics and therapeutics. The options enable supporting shareholders to further share in our success. I am very pleased to say the raising received strong support from existing institutional and new sophisticated investors and from management and the Board. The challenge in front of the company is to prove the potential of our proprietary exosome platform and recent achievements across our research tools, diagnostics and therapeutics. We are now well-funded to leverage our existing product portfolio while exploring strategic M&A opportunities.”

- **First order received from Promega who is selling our kits worldwide**
- **Breakthrough exosome therapy to target and kill breast cancer**
- **SubB2M-CA125 ovarian cancer test analytical validation**
- **EXO-NET Platform expands to isolating brain derived exosomes for Alzheimer’s Disease**
- **Capital raise of \$9.4m under a placement to institutional and sophisticated investors (\$7m and SPP (\$2.4m received post year-end)**
- **Cash balance of \$9.233m at 30 June 2024**

### 1 EXOSOME PROGRAMS

#### 1.1 PAN-EXOSOME CAPTURE TECHNOLOGY (EXO-NET)

INOVIQ has commercialised its proprietary exosome capture technology with speed, efficiency and specificity advantages for exosome biomarker discovery and diagnostics.

During the quarter, INOVIQ received its first order for EXO-NET under the Supply and Distribution Agreement with US based Promega Corporation, a global provider of research tools and technologies. This order was fully prepaid and partially filled at 30 June 2024.

INOVIQ continues to progress business development activities with exosome key opinion leaders, core research facilities, contract research organisations and biotechnology/pharmaceutical companies developing exosome diagnostics. INOVIQ and Promega attended multiple diagnostic conferences during the period and delivered poster presentations showcasing the use of both manual and high-throughput EXO-NET in breast and ovarian cancers.

On 17 May 2024, an EXO-NET paper entitled High-Throughput Surface Epitope Immunoaffinity Isolation of Extracellular Vesicles and Downstream Analysis was published online in *Biology Methods & Protocols* and is available [here](#).

## 1.2 EXOSOME OVARIAN CANCER SCREENING TEST (EXO-OC)

The Ovarian Cancer Screening test is an exosome multi-marker test in development for screening high-risk women for ovarian cancer.

University of Queensland has secured 500 ovarian cancer samples and matched healthy controls using EXO-NET to capture exosomes for a biomarker validation study expected to complete by the end of CY 2024.

## 1.3 BRAIN-DERIVED EXOSOME CAPTURE TECHNOLOGY (NEURO-NET)

On 12 June 2024, INOVIQ announced that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer's Disease. NEURO-NET captures exosomes released from brain cells. Exosomes provide a "fingerprint" of the health or disease status of the parent cell and can cross the "blood-brain barrier", making them promising candidates as diagnostics for neurological diseases. Additionally, exosomes can be weaponized to target brain cells in the treatment of neurological conditions.

Initial analytical and clinical validation of NEURO-NET showed that exosomes isolated from blood contained proteins known to be expressed by brain cells including the identification of known Alzheimer's biomarkers that cannot be detected by other methods.

Analysis of NEURO-NET-captured exosomes identified more than 200 proteins that were differentially expressed in Alzheimer's disease (AD) patients when compared with healthy individuals. These results were further validated by a larger study (48 cases and 44 controls) conducted by the Walter & Elisa Hall Institute, confirming the presence of previously identified biomarkers of AD. Importantly, 47 proteins were uniquely expressed in exosomes isolated from AD blood samples and provided robust discrimination between cases and controls.

INOVIQ has presented these data to diagnostic and biopharma companies interested in using NEURO-NET to improve existing blood-based neurodegenerative disease tests and develop companion diagnostics for neuro-therapeutics.

## 1.4 EXOSOME THERAPEUTICS

INOVIQ is developing exosome therapeutics to target and kill cancer. This is the very exciting extension of our diagnostic work.

INOVIQ's exosome therapeutics program uses chimeric antigen receptor (CAR)-exosomes that are released from genetically engineered CAR-T and CAR-NK cells. These CAR-exosomes have enormous potential as cell-free therapeutics, with manufacturing, safety and efficacy advantages over autologous cell therapies for treating solid tumors. CAR-exosomes inherit the tumor-targeting and cytotoxic capabilities of their parent CAR-T/NK cells, specifically targeting and killing cancer cells.

On 3 June 2024 INOVIQ announced that it had successfully produced and isolated engineered exosomes (EEVs) that target and kill breast cancer cells *in vitro*. A proof-of-concept study demonstrated that a breast cancer targeting protein (CAR) was expressed in exosomes released by immune cells. The engineered exosomes were isolated and concentrated from immune cell-conditioned media using INOVIQ's proprietary EXO-ACE™ technology (for isolating exosomes at scale for therapeutic use). EXO-ACE recovered more than 80% of exosomes from cell-conditioned media with over 95% purity. When treated with these exosomes, 75% of breast cancer cells underwent cell death within 72 hours. Based on these excellent results, INOVIQ is progressing its exosome therapeutics program, initially focusing on immune-cell derived exosome therapeutics for metastatic breast and ovarian cancers.

The Company continued to establish its Master Cell Bank and progress its engineering program for CAR-exosomes to enable further *in vitro* efficacy testing from NK-cell lines.

## 2. TEST FOR BREAST CANCER MONITORING (NEU-CA15-3)

neu-CA15-3 is a simple, accurate and affordable blood test for monitoring breast cancer in women. The immunoassay has been designed using a CA15-3 monoclonal capture antibody combined with INOVIQ's proprietary detection reagent to monitor CA15-3 produced by cancer cells, resulting in improved specificity for cancer and potentially less false positives.

The test has been clinically validated to detect breast cancer across all stages, key breast cancer types and subtypes, and is effective for breast cancer monitoring. INOVIQ has initiated discussions with potential partners and key opinion leaders to secure a laboratory partner in the US for commercialisation of the test. A scientific paper on neuCA15-3 has been prepared for submission to an international peer-reviewed scientific journal.

The Company also initiated a feasibility program to transfer the current ELISA to a bead-based assay that can be used on high-throughput automated laboratory equipment. Plans for an in-clinic study of the test for monitoring treatment response were also progressed.

## 3. TEST FOR OVARIAN CANCER MONITORING (NEU-CA125)

neu-CA125 is a simple, accurate and affordable blood test for monitoring ovarian cancer. The immunoassay has been designed using a CA125 monoclonal capture antibody combined with INOVIQ's proprietary SubB2M detection reagent to monitor CA125 produced by cancer cells, resulting in improved specificity for cancer and potentially less false positives.

On 19 April 2024, INOVIQ announced the successful completion of an analytical validation study for its SubB2M blood test for ovarian cancer. Overall, the test correctly identified 85% of all samples tested including 76% of the cancer samples and 94% of the cancer free samples. Analytical validation confirmed that the test is working properly and can reliably detect women with ovarian cancer. Further development of neu-CA125 test will commence upon receipt of new fit-for-purpose CA125 antibodies currently in production by a contract manufacturer.

## 4. FINANCIAL UPDATE

INOVIQ has \$9.233m cash at 30 June 2024. The SPP completed in early July 2024, delivering a further \$2.379m (before costs) post period end.

Operating cash receipts during the quarter included:

- \$261k from EXO-NET and hTERT sales during the quarter (March 2024 quarter - \$119k); and
- \$51k of bank interest (March 2024 quarter - \$64k).

Net cash used in operating activities for the quarter was \$1,512k with the main outflows being:

- Research and Development (R&D) expenditure of \$751k (March 2024 quarter - \$638k);
- Non-R&D staff costs of \$399k (March 2024 quarter - \$424k); and
- Administration, corporate and leased asset costs of \$640k (March 2024 quarter - \$424k).

Payments in section 6.1 of the accompanying Appendix 4C relate to Director fees and superannuation paid during the quarter. Payments in section 6.2 relate to corporate advisory fees (\$30k) and financial advisory fees (\$189k) in connection with the June 2024 capital raise, paid to Kidder Williams, a related party of IIQ Chairman, David Williams.

## 5. CAPITAL RAISE

In June INOVIQ completed a placement to institutional and sophisticated investors, raising \$7.0 million (before costs) via 14 million new fully paid ordinary shares in the Company at \$0.50 per Share, with one free quoted option for every two new Shares issued under the Placement with an exercise price of \$1.00 and two-year expiry. The pricing of the Placement represented an 11.5% discount to the last traded market price. \$0.25m (500,000 Shares) of the Placement (and 250,000 attaching Placement Options), representing the Board's participation in the capital raise, are subject to shareholder approval at a general meeting to be held on 21 August 2024. A link to the EGM Notice of Meeting is available [here](#).

On 5 July 2024 INOVIQ announced the successful completion of the share purchase plan (SPP), with applications totalling \$7.293 million, exceeding the initial target of \$2m. INOVIQ Directors exercised discretion to accept allocations to the maximum capacity of A\$2.379m and scale back applications pro-rata. The SPP also provided investors with one free quoted option for every two new Shares issued at an exercise price of \$1.00 expiring on 8 July 2026.

## 6. INVESTOR EVENTS

On 13 June 2024, Dr Learne Hinch delivered an investor presentation via the MST Access - *Hidden Gems in Life Sciences* webinar. A recording of the presentation is available [here](#).

Authorised for release by the INOVIQ Limited Board of Directors.

### FURTHER INFORMATION

**Dr Learne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**David Williams**  
Chairman  
E [dwilliams@kidder.com.au](mailto:dwilliams@kidder.com.au)  
M +61 414 383 593

### ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company pioneering next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and specific EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. Learn more about INOVIQ at [www.inoviq.com](http://www.inoviq.com).

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

INOVIQ LIMITED

**ABN**

58 009 070 384

**Quarter ended ("current quarter")**

30 June 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	261	660
1.2 Payments for		
(a) research and development ( <i>including allocated staff costs</i> )	(751)	(2,572)
(b) advertising and marketing	(22)	(201)
(c) product manufacturing and operating costs	(4)	(81)
(d) staff costs ( <i>other than R&amp;D staff</i> )	(399)	(1,657)
(e) administration and corporate costs	(555)	(1,654)
(f) leased assets	(85)	(327)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	51	274
1.5 Interest and other costs of finance paid	(8)	(41)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	949
1.8 Other	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(1,512)</b>	<b>(4,650)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	(8)	(161)
(j) investments	-	-
(k) intellectual property	-	(14)

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(l) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(8)</b>	<b>(175)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	6,750	6,750
3.2 Proceeds from issue of convertible debt securities	-	-
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	(509)	(509)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>6,241</b>	<b>6,241</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	4,510	7,813
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,512)	(4,650)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(8)	(175)
4.4	Net cash from capital raising (item 3.10 above)	6,241	6,241
4.5	Effect of movement in exchange rates on cash held	2	4
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>9,233</b>	<b>9,233</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b>	<b>Current quarter</b>	<b>Previous quarter</b>
	at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>\$A'000</b>	<b>\$A'000</b>
5.1	Bank balances	912	689
5.2	Call deposits	8,321	3,821
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>9,233</b>	<b>4,510</b>

**6. Payments to related parties of the entity and their associates**

6.1	Aggregate amount of payments to related parties and their associates included in item 1	75
6.2	Aggregate amount of payments to related parties and their associates included in item 2	219

**Current quarter**  
**\$A'000**

Payments in 6.1 relate to Director fees and superannuation paid during the quarter.

Payments in 6.2 relate to payment of corporate advisory fees (\$30k) and financial advisory fees (\$189k) during the quarter to Kidder Williams, a related party of Company Chair, David Williams.

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

**7. Financing facilities**

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	20	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-

7.5 **Unused financing facilities available at quarter end** 20

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Relates to the corporate credit card facility with the National Australia Bank.

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	(1,512)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	9,233
8.3 Unused finance facilities available at quarter end (Item 7.5)	20
8.4 Total available funding (Item 8.2 + Item 8.3)	9,253
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	6.1

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2024

Authorised by: By the Board of Directors

Authorised for release by Company Secretary – Mark Edwards  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.